Aktie A2DT59 DOVA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Dova Pharmaceuticals, Inc.

Aktien

A2DT59

US25985T1025

DOVA

Verzögert Nasdaq
Andere Börsenplätze
 		% 5 Tage % 1. Jan.
- USD -.--% Intraday Chart für Dova Pharmaceuticals, Inc. -0,07 % +269,92 %
2019 Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
2019 Transcript : Dova Pharmaceuticals, Inc. - Special Call

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase
Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index
Dova Pharmaceuticals, Inc. Announces Executive Changes
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index
WeissLaw LLP Investigates Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.
Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results
Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DT59 Aktie
  4. Nachrichten Dova Pharmaceuticals, Inc.
  5. Andere Sprachen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT